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Abstract
Purpose—To date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression 
as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of 
EGFR amplification in blood-derived cell-free tumor DNA (cfDNA) across diverse cancers and 
the role of anti-EGFR therapies in achieving response.
Methods—We assessed EGFR amplification status among 28,584 patients with malignancies 
evaluated by clinical-grade next-generation sequencing (NGS) of blood-derived cfDNA (54- to 73-
gene panel). Furthermore, we curated the clinical characteristics of 1,434 patients at the University 
of California San Diego who had cfDNA testing by this NGS test.
Results—Overall, EGFR amplification was detected in cfDNA from 8.5% of patients (2,423 of 
28,584), most commonly in colorectal (16.3% [458 of 2,807]), non-small-cell lung (9.0% [1,096 
of 12,197]), and genitourinary cancers (8.1% [170 of 2,104]). Most patients had genomic 
coalterations (96.9% [95 of 98]), frequently involving genes affecting other tyrosine kinases 
(72.4% [71 of 98]), mitogen-activated protein kinase cascades (56.1% [55 of 98]), cell-cycle-
associated signals (52.0% [51 of 98]), and the phosphoinositide 3-kinase pathway (35.7% [35 of 
98]). EGFR amplification emerged in serial cfDNA after various anticancer therapies (n = 6), 
including checkpoint inhibitors (n = 4), suggesting a possible role for these amplifications in 
acquired resistance. Nine evaluable patients with EGFR amplification were treated with anti-
EGFR-based regimens; five (55.6%) achieved partial responses, including three patients whose 
tissue NGS lacked EGFR amplification.
Conclusion—EGFR amplification was detected in cfDNA among 8.5% of 28,584 diverse 
cancers. Most patients had coexisting alterations. Responses were observed in five of nine patients 
who received EGFR inhibitors. Incorporating EGFR inhibitors into the treatment regimens of 
patients harboring EGFR amplification in cfDNA merits additional study.
INTRODUCTION
Epidermal growth factor receptor (EGFR), also known as human epidermal growth factor 
receptor 1 (HER1) or ErbB1, is a receptor tyrosine kinase that belongs to the ErbB family 
proteins. Along with EGFR, the ErbB family includes HER2 (ErbB2), HER3 (ErbB3), and 
HER4 (ErbB4). When receptor-specific ligands bind to the extracellular domain of the 
EGFR, it forms a homodimer (EGFR-EGFR) or heterodimer (eg, EGFR-HER2, EGFR-
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HER3) that leads to the activation of receptors through ATP-dependent phosphorylation of 
tyrosine residues in the EGFR intracellular domain. Activation of EGFR leads to multiple 
downstream signals, including mitogen-activated protein kinase and phosphoinositide 3-
kinase pathways, which enhances cell proliferation and survival.1,2
Functional activation of EGFR via mutation or amplification/overexpression has been 
identified in many tumor types, including lung, head and neck, gastroesophageal, and 
colorectal cancers, and has been associated with proliferation, invasion, and metastasis.3,4 
Alterations in EGFR have also been linked to primary resistance and accelerated tumor 
growth (designated as hyperprogression) from immune checkpoint inhibitors.5–7 Because of 
its critical role in tumor aggressiveness, EGFR has been an attractive target for anticancer 
therapy.1 To date, there are various anti-EGFR therapies that are US Food and Drug 
Administration approved, including erlotinib, gefitinib, afatinib, and osimertinib for non-
small-cell lung cancer (NSCLC) with specific activating EGFR mutations,8 cetuximab and 
panitumumab for colorectal cancer without KRAS or NRAS mutations,9 cetuximab for head 
and neck cancer,10 and necitumumab for squamous cell carcinoma of lung.11
Biomarkers to predict response to anti-EGFR therapies have been studied extensively. EGFR 
and KRAS mutation status are widely used in lung and colorectal cancer, respectively.
8,9,12,13
 In contrast, EGFR amplification and overexpression in tissue have not been well 
established as reliable biomarkers for anti-EGFR agents, (selected studies that investigated 
EGFR amplification/overexpression as a predictive marker for anti-EGFR therapies are 
summarized in the Data Supplement)11,14–19. Overall, a meta-analysis concluded that tissue 
EGFR amplification status could not be demonstrated to be a consistent biomarker to predict 
the outcome from anti- EGFR therapies in colorectal cancer.20
Although it is somewhat surprising that tissue EGFR amplification/expression status has not 
been established as a reliable biomarker for anti-EGFR therapies, potential reasons include 
heterogeneity between primary and metastatic lesions, dynamic changes in genomic 
alterations that may emerge along with therapeutic pressure or progression, presence of 
genomic coalterations associated with resistance, and potential differences in response to 
copy number gain due to aneuploidy versus focal EGFR amplification.21–23 Use of plasma-
derived cell-free tumor DNA (cfDNA) to assess EGFR status by next-generation sequencing 
(NGS) could conceivably overcome some of these limitations by detecting tumor-specific 
alterations that are shed into the bloodstream from multiple metastatic sites as well as the 
primary cancer.23–29
Herein, we examined the genomic landscape of EGFR amplification by interrogating blood-
derived cfDNA from 28,584 patients with diverse malignancies using clinical-grade NGS. 
Furthermore, we investigated the clinical characteristics, concordance between tissue NGS 
and cfDNA, and therapeutic outcome after anti-EGFR therapies among a subset of 1,434 
clinically annotated patients at the University of California, San Diego (UCSD), Moores 
Cancer Center.
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METHODS
Patients
The genomic landscape of EGFR amplification among 28,584 diverse solid cancers that 
were referred to Guardant Health from March 2014 to February 2017, were evaluated. 
Furthermore, we have curated the clinical characteristics of 1,434 evaluable patients with 
diverse cancers at UCSD who had cfDNA testing at Guardant Health starting in March 
2014. All investigations followed the guidelines of the UCSD Institutional Review Board for 
data collection (Profile Related Evidence Determining Individualized Cancer Therapy; 
ClinicalTrials.gov identifier: NCT02478931) and for any investigational therapies for which 
the patients consented (Data Supplement).
NGS for cfDNA and Tissue
All cfDNA analyses were performed at Guardant Health as previously described (Data 
Supplement).26 Tissue NGS was performed at Foundation Medicine, as previously 
described30 (Data Supplement).
End Points and Statistical Methods
Patient characteristics, prevalence of EGFR amplification, and genomic coalterations were 
summarized by descriptive statistics. Fisher’s exact test was used for categorical variables. 
Concordances between cfDNA and tissue DNA were described by percentage of 
concordance and κ value with standard error. Antitumor response was evaluated using 
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Progression-free survival was 
defined as the time from treatment initiation to disease progression. Patients who had not 
experienced disease progression at the time of last follow-up were censored at that time 
point. Statistical analysis was performed with the assistance of author R.O.
RESULTS
Prevalence of EGFR Amplification in cfDNA Testing in Diverse Cancers
Among 28,584 patients with diverse solid malignancies whose cfDNA was evaluated at a 
central laboratory, 8.5% (n = 2,423) had EGFR amplification. The most common tumors 
harboring EGFR amplification were colorectal cancer (16.3% [458 of 2,807]), followed by 
NSCLC (9.0% [1,096 of 12,197]), genitourinary cancers (8.1% [170 of 2,104]), cutaneous 
tumors (7.4% [45 of 610]), and breast cancer (7.3% [328 of 4,518]; Fig 1A).
Prevalence of EGFR Amplification in cfDNA Testing in Patients With Diverse Cancers From 
UCSD Cohort
Among the UCSD cohort of 1,434 patients (Data Supplement), overall, 6.8% of patients (98 
of 1,434) had EGFR amplification, including 86 patients detected at their first cfDNA 
evaluation and 12 patients with emerging EGFR amplification at the time of subsequent 
cfDNA evaluation. The most common cancers (with more than 10 samples) harboring EGFR 
amplification were breast (14.7% [16 of 109]) and colorectal cancer (12.7% [16 of 126]; Fig 
1B).
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Genomic Coalterations Associated With EGFR Amplification (analysis of cfDNA)
Among 98 patients with EGFR amplification at UCSD, the median number of characterized 
genomic alterations was 5.0 (range, 0 to 17; excluding the EGFR amplification), and the 
median number of alterations among patients without EGFR amplification (n = 1,336) was 
significantly less (median, 1.0; range, 0 to 20; P < .001). The most common coalterations 
associated with EGFR amplification were in the following genes: TP53 (65.3% [64 of 98]), 
followed by BRAF (42.9% [42 of 98]), MET (40.8% [40 of 98]), CDK6 (32.7% [32 of 98]), 
and PIK3CA (32.7% [32 of 98]; Fig 2; Appendix Fig A1). On the other hand, coalterations 
in these genes were found significantly less frequently among patients without EGFR 
amplification: coalterations in TP53 in 32.1% of patients, BRAF (4.9%), MET (2.5%), 
CDK6 (1.4%), and PIK3CA (8.8%; all P < .001; Fig 2). When the genes were categorized 
according to their oncogenic roles, 72.4% (71 of 98) of patients with EGFR amplification 
had at least one characterized coalteration in tyrosine kinase family genes, 56.1% (55 of 98) 
in genes involved in mitogen-activated protein kinase cascades, 52.0% (51 of 98) in cell-
cycle–associated genes, and 35.7% (35 of 98) in phosphoinositide 3-kinase signaling 
pathway genes (Appendix Fig A2).
Potential Targeted Therapies for Coalterations Associated With EGFR Amplification
In the UCSD cohort of 98 patients positive for EGFR amplification, 96.9% (95 of 98) of 
patient tumors had at least one characterized coalteration. All these 95 malignancies 
harbored at least one characterized coalteration potentially targetable with US Food and 
Drug Administration–approved agents as on- or off-label use.
Clinical Characteristics of Patients Who Had Emerging EGFR Amplification With Serial 
cfDNA Analyses
Six patients who initially tested negative for EGFR amplification in both tissue NGS and 
cfDNA were found to have emerging EGFR amplification with serial cfDNA analyses. (A 
total of 324 patients who initially tested negative had serial testing.) Patterns of genomic 
evolution differed from patient to patient. Emergence of EGFR amplification was seen 
among patients in a variety of situations, including in four patients who received checkpoint 
inhibitors, although two of the four patients also had other intervening therapies (Fig 3; Data 
Supplement).
Concordance of EGFR Amplification Between cfDNA and Tissue NGS
Among patients from the UCSD cohort whose cfDNA was evaluated, tissue NGS was 
available in 787 cases. The overall concordance rate for EGFR amplification between tissue 
and cfDNA NGS was 89.3% (Data Supplement). A shorter interval between the date of 
tissue biopsy (for tissue NGS) and blood draw (for cfDNA) was associated with statistically 
higher concordance rate (≤ 6 months: 92.1% v > 6 months: 85.8%; P = .005; Data 
Supplement).
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Efficacy of Anti-EGFR Therapies Among Patients With EGFR Amplification Detected by 
cfDNA Analysis
Among 98 patients with EGFR amplification, patients harboring coactivating EGFR 
mutations were excluded from the analysis, because the response from anti-EGFR therapies 
could be confounded by these mutations (n = 26). Among 72 patients with EGFR 
amplification (without coexisting EGFR mutations), nine received treatment regimens that 
included anti-EGFR agents after cfDNA testing (Appendix Fig A3). Among these nine 
individuals, EGFR plasma copy numbers ranged from 2.37 to 143.94 (1 + [n = 1], 2+ [n = 
4], and 3+ [n = 4]) across six different cancer diagnoses: tonsillar squamous cell carcinoma 
(n = 1), triple-negative breast cancer (n = 1), adenocarcinoma of unknown primary (n = 1), 
gastroesophageal junction adenocarcinoma (n = 1), adrenocortical carcinoma (n = 2), and 
colorectal cancer (n = 3). Types of anti-EGFR-based regimens were as follows: monotherapy 
with anti-EGFR antibody (n = 1), anti-EGFR antibody plus another targeted agent (n = 1), 
EGFR tyrosine kinase inhibitor plus another targeted agent (n = 1), anti-EGFR antibody plus 
cytotoxic agents (n = 2), and dual anti-EGFR therapy-based regimens (combination of anti-
EGFR antibody plus EGFR tyrosine kinase inhibitor; n = 4). Overall, tumor reduction was 
seen in six of nine patients (66.7%), including five (55.6%) who attained a partial response 
(PR) per RECIST 1.1 (Fig 4). Illustrative responders are depicted in Figure 5.28
DISCUSSION
We describe the comprehensive landscape of EGFR amplification in cfDNA among 28,584 
patients with varied malignancies whose liquid biopsy was evaluated at a central, clinical-
grade laboratory. Overall, 8.5% of patients harbored an EGFR amplification in their blood-
derived cfDNA, with EGFR amplifications being most common in colorectal cancer (16.3% 
of patients), NSCLC (9.0%), genitourinary cancers (8.1%), cutaneous tumors (7.4%), and 
breast malignancies (7.3%). Having high copy number amplification with greater than 4.00-
fold EGFR amplification was seen in 1.0% of patients; most patients had amplification 
levels between 2.41-fold and 4.00-fold (4.6%; Fig 1).
EGFR amplification/overexpression is associated with cancer aggressiveness.3,4 Even so, 
previous studies failed to demonstrate tissue-based assessment of EGFR overexpression to 
be a reliable biomarker to predict clinical outcomes after anti-EGFR therapies (Data 
Supplement).11,14–20 These observations are consistent with data from meta-analyses and 
clinical experience suggesting that, counterintuitively, genomic biomarkers correlate better 
with response than protein expression, perhaps because of technical limitations associated 
with assessment of immunohistochemistry staining.31–34
Prior studies looking at the relationship between EGFR amplification and therapeutic 
response to EGFR inhibitors showed inconsistent results (Data Supplement). However, one 
potential explanation is tumor heterogeneity, especially between primary and metastatic 
lesions and even between distinct foci at the same site. Indeed, Pectasides et al23 
demonstrated that, among patients with treatment-naive metastatic gastroesophageal cancers, 
discordant gene alterations between primary and metastatic tissue were common, being seen 
in 42% of patients. Interestingly, the discordance rate was higher for gene amplifications. 
However, among discordant cases, high concordance (87.5%) was seen between metastatic 
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tissue and cfDNA profiling. The concordance rate documented by Pectasides et al23 is 
similar to that in the current report that showed an 89.3% concordance rate for EGFR 
amplification between cfDNA and tissue NGS (Data Supplement). These results suggest that 
biopsy of a limited tumor focus can misrepresent the overall genomic condition of disease 
and, thus, may not be a completely accurate guide for targeted treatment. NGS of cfDNA 
derived from plasma may attenuate this challenge. Consistent with this concept, among our 
nine evaluable patients who harbored EGFR amplification by cfDNA analysis, anti-EGFR-
based therapies led to tumor reduction in 66.7% (six of nine) including 55.6% (five of nine) 
who achieved a PR (Fig 4). Our data are comparable to those of Maron et al,35 who showed 
a 58% (four of seven) objective response rate among patients with EGFR-amplified gastric 
cancer (all seven patients were positive for EGFR amplification by tissue NGS, and six were 
positive by cfDNA analysis). Similarly, ERBB2 amplification detected by cfDNA analysis 
was highly predictive of anti-HER2 targeted therapy response.36
There were additional noteworthy observations from our patients treated with anti- EGFR-
based therapies: three of five patients whose EGFR amplification was only detected in 
cfDNA (negative on tissue NGS) still demonstrated a PR (including one patient treated with 
cetuximab monotherapy [patient 57]), PRs were seen across different degrees of EGFR 
amplification status (from copy number amplification of 2.37 to 143.94), and three of four 
patients who received dual anti-EGFR inhibitors (coadministration of antibody and tyrosine 
kinase inhibitor for EGFR) achieved tumor reduction. Importantly, dual inhibition with both 
an antibody and a small molecule targeting the same receptor has been investigated among 
patients with HER2-positive breast cancer and reported to have significantly higher response 
rates when compared with either drug alone.37 Efficacy of dual-targeted therapy was also 
seen in patients with HER2-positive colon cancer that showed a 30% response rate with 
trastuzumab/lapatinib combination.38 Similarly, early-phase clinical trials with dual-EGFR 
inhibition (cetuximab/afatinib- or cetuximab/erlotinib-based therapy) showed favorable 
clinical outcomes among patients with refractory NSCLC and colorectal cancer.39–43 The 
mechanism by which dual inhibition operates is not fully elucidated, but preclinical studies 
suggest that kinase receptors may function via kinase-dependent and -independent 
mechanisms.44,45
Although responses were seen in more than half of the patients with EGFR amplification 
treated with EGFR inhibitors, not all patients responded. Our study demonstrates that 
patients whose tumors harbor EGFR amplifications have considerably more cfDNA genomic 
alterations than those without EGFR amplification (median, 5.0 v 1.0 genomic coalteration 
per patient; P < .001). Therefore, primary or secondary resistance could be on the basis of 
the need to target coexisting activated pathways. Indeed, as seen in Figure 4, of the nine 
patients with cfDNA EGFR amplification treated with EGFR-targeting agents, the four 
nonresponders had six to nine genomic coalterations, whereas the five responders had only 
zero to five coalterations per patient. Furthermore, the patient with the greatest tumor 
regression and most durable response (Fig 4, patient 25; progression-free survival, 18 
months) demonstrated no genomic coalterations on cfDNA. Of interest, patients who failed 
to achieve prolonged responses had coalterations in specific oncogenic pathways, including 
CDK4/6, MET, PDGFRA, ERBB2, FGFR1, PIK3CA, AKT1, KRAS, and BRAF, some of 
which are known to be associated with resistance to anti-EGFR therapies.46,47 Considering 
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that patients with EGFR amplification had frequent potentially tractable coalterations (Fig 2; 
Appendix Figs A1 and A2), a customized combination strategy may be required.48,49 
Although current findings do not provide definitive proof of antitumor activity, these 
observations suggest that studies of appropriate combinations of drugs that target both the 
EGFR amplification and the coalterations would be of interest. Investigation of such an 
approach is currently ongoing (ClinicalTrial.gov identifier: NCT02534675; I-PREDICT 
[Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for 
Advanced or Poor Prognosis Cancers]).
Interestingly, Oxnard et al50 and Abbosh et al51 have shown that more extensive disease 
burden corresponds to higher rates of cfDNA detection. The finding of higher numbers of 
comutations in patients harboring EGFR amplification events could therefore be a possible 
effect of increased aggressiveness and higher tumor burden (with more extensive disease 
shedding more cfDNA and thus permitting detection of more alterations), or, alternatively, 
higher numbers of comutations could be a cause of increased aggressiveness. In this regard, 
we have recently found that higher percent cfDNA correlates with higher number of 
alterations. Furthermore, both higher percent cfDNA and higher number of alterations were 
independently associated with shorter survival after multivariate analysis. This observation 
suggests that the association between survival and number of alterations is independent of 
the percent cfDNA (with the latter correlating with disease burden; unpublished data).
In the current report, we also identified patients whose EGFR amplifications emerged in 
their liquid biopsy with serial testing after a variety of anticancer therapies (n = 6; Fig 3). 
For instance, one patient who was treated with the EGFR tyrosine kinase inhibitor erlotinib 
showed emergence of blood-derived EGFR amplification after disease progression (Fig 4), 
consistent with a previous report demonstrating tumor evolution with EGFR amplification as 
a potential resistance mechanism to EGFR tyrosine kinase inhibitor administration.52 
Perhaps relevant in this regard, all of our responders had an EGFR antibody included in their 
regimen. Four patients were found to have emerging EGFR amplification after disease 
progression while receiving checkpoint inhibitors. Although EGFR alterations are reported 
to be associated with primary resistance and hyperprogression after immune checkpoint 
blockade,6,7 the current observation may suggest that EGFR amplification can also be a 
possible mechanism for acquired resistance after checkpoint blockades. For those patients 
with clonal evolution that includes EGFR amplification after anti-PD-1 checkpoint blockade, 
addition of anti-EGFR therapy may overcome resistance. This is suggested by our 
representative patient who was treated with pembrolizumab, had a mixed response, and then 
received erlotinib and cetuximab (in addition to ongoing pembrolizumab) and showed 
reduction in EGFR cfDNA copy number as well as regression of tumor foci and 
improvement in pain and performance status (Fig 4, patient 26; Figs 5A and 5B).39,40 
Additional investigation is required to understand the complex interplay of response and 
resistance associated with EGFR amplifications, EGFR-targeting pharmaceuticals, and 
checkpoint blockade.
There were several limitations to the current study. First, the investigation of clinical 
correlates in the UCSD cohort was performed retrospectively. Second, for the large de-
identified database of 28,584 patients, sample size bias cannot be excluded, because the 
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number of each cancer type was based on the number of samples sent for cfDNA testing by 
treating physicians. Moreover, the diagnosis was determined based on the submitting 
physician’s designation. Third, in the de-identified database, we were not able to evaluate 
the history of systemic therapy that may have affected the dynamics of cfDNA. It is possible 
that some of the EGFR amplifications emerged because of therapeutic pressure. Last, 
technological methods and definition of EGFR amplification differed between tissue NGS 
and cfDNA analyses; thus, direct comparison between those two tests may be challenging. 
Yet, despite these limitations, the study provides a comprehensive analysis of EGFR 
amplification detected from plasma-derived cfDNA in a wide range of malignancies.
In conclusion, among patients with diverse cancers (n = 28,584 from a central laboratory), 
cfDNA interrogated by clinical-grade NGS revealed that 8.5% of patients with solid cancers 
harbored EGFR amplification. Frequencies of EGFR amplification differed between cancer 
types. Most patients found to have EGFR amplification also had genomic coalterations that 
are, in theory, pharmacologically tractable (96.9% [95 of 98]) by available drugs. Anti-
EGFR- based therapies among patients found to have EGFR amplification by cfDNA 
analysis achieved responses in 55.6% of patients (five of nine), including in three individuals 
who failed to show EGFR amplification on tissue NGS. Incorporating EGFR inhibitors into 
regimens administered to patients with EGFR amplification in cfDNA warrants additional 
investigation.
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Fig 1. 
(A) Prevalence of EGFR amplification by cell-free DNA (cfDNA) among diverse cancer 
from central laboratory (n = 28,584). Among 28,584 patients with diverse cancer whose 
cfDNA was evaluated at central laboratory, overall 8.5% of patients (n = 2,423) had EGFR 
amplification (median copy number amplification [CNA], 2.55; range, 2.14 to 143.94). 
Overall, 1+, 2+, and 3+ EGFR CNAs were found in 2.9% (n = 828), 4.6% (n = 1,315), and 
1.0% (n = 280) of patients, respectively. The most common cancer harboring EGFR 
amplification was colorectal cancer (16.3% [458 of 2,807]), followed by non-small-cell lung 
cancer (9.0% [1,096 of 12,197]) and genitourinary cancers (8.1% [170 of 2,104]). (B) 
Prevalence of EGFR amplification by cfDNA among diverse cancer from University of 
California, San Diego (UCSD), cohort (n = 1,434). Among UCSD cohort (n = 1,434), 
overall 6.8% of patients (98 of 1,434) had EGFR amplification (median CNA, 2.55; range, 
2.18 to 143.94). CNAs of 1+, 2+, and 3+ were found in 3.0% (n = 43), 3.3% (n = 48), and 
0.5% (n = 7) of patients, respectively. The most common cancer harboring EGFR 
amplification was small-cell lung cancer (30.0% [three of 10]), followed by breast cancer 
(14.7% [16 of 109]) and colorectal cancer (12.6% [16 of 127]). ⋆Includes 25 patients with 
lung, adenocarcinoma (+ [n = 10], ++ [n = 12], +++ [n = 3]) and three patients with lung, 
squamous cell carcinoma (+ [n = 2], ++ [n = 1]). †Includes four patients with carcinoma of 
unknown primary (+ [n = 1], ++ [n = 2], +++ [n = 1]) and two patients with adrenocortical 
carcinoma (++ [n = 2]).
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Fig 2. 
Comparison of genomic alterations in patients with and without EGFR amplification 
(analysis of cell-free DNA [cfDNA]; n = 1,434). The most common cogenomic alterations 
associated with EGFR amplification was TP53 (65.3% [64 of 98]), followed by BRAF 
(42.9% [42 of 98]), MET (40.8% [40 of 98]), CDK6 (32.7% [32 of 98]), and PIK3CA 
(32.7% [32 of 98]). On the other hand, coalterations in these genes were significantly less 
associated among patients without EGFR amplification (alterations found: 32.1% in TP53, 
4.9% in BRAF, 2.5% in MET, 1.4% in CDK6, and 8.8% in PIK3CA; all P < .001). ⋆P < .
001. ⋆⋆P = .027 by Fisher’s exact test. †EGFR alterations other than amplification. Variants 
of unknown significance excluded.
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Fig 3. 
Overview of patients who had emerging EGFR amplification with serial cell-free DNA 
(cfDNA) analysis after anticancer therapies (Data Supplement). Six patients who initially 
tested negative for EGFR amplification on tissue next-generation sequencing as well as 
cfDNA were found to have EGFR amplification with serial cfDNA analyses after various 
treatments; in four patients, treatment regimens included immune checkpoint inhibitors (n = 
4; patients 30, 33, 43, and 46). EGFR, epidermal growth factor receptor; FOLFIRI, 
fluorouracil, leucovorin, and irinotecan; NGS, next-generation sequencing; TKI, tyrosine 
kinase inhibitor.
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Fig 4. 
Efficacy of anti-epidermal growth factor receptor (EGFR)-based therapies among patients 
with EGFR amplification (amp). Nine patients with EGFR amplification were evaluable for 
response from anti-EGFR-based therapies. Overall, tumor reduction was seen in six of nine 
(66.7%), including five of nine (55.6%) patients with partial response per Response 
Evaluation Criteria in Solid Tumors 1.1. (⋆) Patient was experiencing mixed response 
(mixture of disease stability and progressive disease) with pembrolizumab monotherapy 
after 15 months. Anti-EGFR agents were added for emerging EGFR amplification detected 
in cfDNA (see also Figure 5). cfDNA, cell-free DNA; CNA, copy number amplification; 
EGFR, epidermal growth factor receptor; FOLFIRI, fluorouracil, leucovorin, and irinotecan; 
GE, gastroesophageal; N/A, not applicable; NGS, next-generation sequencing; PFS, 
progression-free survival; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.
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Fig 5. 
Representative cases of patients who achieved tumor reduction with anti-epidermal growth 
factor receptor (EGFR)-based therapies. (A) Patient 26: Dynamic change in serial cell-free 
DNA (cfDNA) along with anti-EGFR therapies. (B) Patient 26: Serial computed tomography 
(CT) images while receiving anti-EGFR therapies (correspond with A). A 55-year-old 
woman with metastatic triple-negative breast cancer to bone and lung was treated with 
pembrolizumab with initial disease stability for more than 1 year, but then progression in the 
bones and deteriorating performance status requiring a wheelchair. cfDNA obtained before 
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treatment did not detect genomic alterations. cfDNA at the time of bone progression 
revealed multiple emerging alterations, including EGFR amplification (3+; plasma copy 
number of 4.88; A). Pembrolizumab was continued and anti-EGFR therapies (erlotinib and 
cetuximab) were added. After starting anti-EGFR agents, the patient achieved 16% tumor 
shrinkage per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (B, left to right), 
with symptomatic improvement allowing the patient to ambulate without narcotics for pain 
control. Repeat cfDNA showed elimination of most alterations, including EGFR 
amplification (A). Therapy with anti-EGFR inhibitors is ongoing at 4+ months. (C) Patient 
57: Serial CT images while receiving anti-EGFR therapy. A 53-year-old woman with 
metastatic rectal adenocarcinoma to the liver and lungs presented after experiencing disease 
progression while receiving two lines of therapies (infusional fluorouracil, leucovorin, and 
oxaliplatin with bevacizumab and fluorouracil, leucovorin, and irinotecan with 
bevacizumab). Tissue next-generation sequencing was negative for EGFR amplification; 
however, cfDNA revealed alterations including EGFR amplification (1+; plasma copy 
number of 2.37). Therapy was started with single-agent cetuximab, and a 44% reduction in 
tumor burden by RECIST 1.1 was seen (progression-free survival, 6.0 months; C, left to 
right). (D) Patient 25: Serial CT images while receiving anti-EGFR therapies. A 68-year-old 
woman was referred with metastatic gastroesophageal junction carcinoma to the liver and 
lymph nodes. Both cfDNA and primary tumor showed EGFR amplification by next-
generation sequencing (EGFR amplification 3+ by cfDNA, plasma copy number of 143.94). 
Therapy with dual anti-EGFR therapy (cetuximab and erlotinib) was started (patient was 
also administered one dose of nivolumab on the basis of programmed death ligand 1 positive 
by immunohistochemistry; however, held because of severe rash). The patient achieved a 
durable partial response28 (70% tumor reduction; progression-free survival, 18 months; D, 
left to right). Serial cfDNA analyses were obtained at 4 months, 12 months, and 17 months 
after the initiation of therapy and were negative for EGFR amplification. Red arrows and 
circles indicate presence of tumor. cfDNA, cell-free DNA.
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